^
    Back
    Association details:
    Biomarker:BRAF V600E
    Cancer:Glioma
    Drug:Mektovi (binimetinib) (MEK inhibitor) +
    Braftovi (encorafenib) (BRAF inhibitor, cRAF inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C1 - Off-label
      (Approved for Melanoma)
    New
    Excerpt:
    BRAFTOVI is a kinase inhibitor indicated, in combination with binimetinib, for the treatment of patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation, as detected by an FDA-approved test.
    Evidence Level:
    Sensitive: C4 – Case Studies
    Source:
    Neurology
    Title:

    BRAFV600E-mutant glioblastoma responds to combination BRAF/MEK inhibition with encorafenib and binimetinib

    Published date:
    05/03/2022
    Excerpt:
    A 25-year-old man with a subtotally resected BRAF-mt astrocytoma with pilocytic features experienced tumor growth after 18 months. Re-resection pathology confirmed high-grade BRAFV600E-mt glioma….He was subsequently started on encorafenib/binimetinib. Follow up MRI demonstrated residual tumor stability with near complete resolution of leptomeningeal disease. He remains progression free after 6 months...encorafenib/binimetinib appear to confer favorable and lasting efficacy for BRAFV600E-mt glioma in both the parenchyma and leptomeninges. To our knowledge, this is the first report of glioma response to these specific agents.